Alcon Withdraws EU Application For Retaane
This article was originally published in The Pink Sheet Daily
Executive Summary
The macular degeneration therapy remains "approvable" in the U.S.
You may also be interested in...
Alcon's Retaane Is Again "Approvable" For Wet AMD; Firm May Pursue Risk Reduction Indication Instead
FDA approval would require another trial, but "given the market and given what we know about the compound, we are not planning on initiating an additional study," firm tells "The Pink Sheet" DAILY.
Alcon's Retaane Is Again "Approvable" For Wet AMD; Firm May Pursue Risk Reduction Indication Instead
FDA approval would require another trial, but "given the market and given what we know about the compound, we are not planning on initiating an additional study," firm tells "The Pink Sheet" DAILY.
Alcon's Retaane "Approvable" For Wet Age-Related Macular Degeneration
The firm plans to meet with FDA "to determine the steps necessary to gain final approval." Alcon says it will discuss ongoing studies with anecortave acetate. The ophthalmic agent passed manufacturing inspections, the firm reports.